1. Home
  2. HIT vs SCYX Comparison

HIT vs SCYX Comparison

Compare HIT & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HIT
  • SCYX
  • Stock Information
  • Founded
  • HIT 1964
  • SCYX 1999
  • Country
  • HIT United States
  • SCYX United States
  • Employees
  • HIT N/A
  • SCYX N/A
  • Industry
  • HIT Specialty Insurers
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • HIT Finance
  • SCYX Health Care
  • Exchange
  • HIT Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • HIT 37.2M
  • SCYX 36.8M
  • IPO Year
  • HIT 2024
  • SCYX 2014
  • Fundamental
  • Price
  • HIT $0.80
  • SCYX $0.74
  • Analyst Decision
  • HIT Strong Buy
  • SCYX
  • Analyst Count
  • HIT 1
  • SCYX 0
  • Target Price
  • HIT $2.50
  • SCYX N/A
  • AVG Volume (30 Days)
  • HIT 242.7K
  • SCYX 170.9K
  • Earning Date
  • HIT 08-15-2025
  • SCYX 08-07-2025
  • Dividend Yield
  • HIT N/A
  • SCYX N/A
  • EPS Growth
  • HIT N/A
  • SCYX N/A
  • EPS
  • HIT 0.02
  • SCYX N/A
  • Revenue
  • HIT $22,380,959.00
  • SCYX $2,630,000.00
  • Revenue This Year
  • HIT $58.79
  • SCYX $463.61
  • Revenue Next Year
  • HIT N/A
  • SCYX $310.80
  • P/E Ratio
  • HIT $44.99
  • SCYX N/A
  • Revenue Growth
  • HIT 11.24
  • SCYX N/A
  • 52 Week Low
  • HIT $0.51
  • SCYX $0.72
  • 52 Week High
  • HIT $7.59
  • SCYX $2.29
  • Technical
  • Relative Strength Index (RSI)
  • HIT N/A
  • SCYX 37.94
  • Support Level
  • HIT N/A
  • SCYX $0.72
  • Resistance Level
  • HIT N/A
  • SCYX $0.85
  • Average True Range (ATR)
  • HIT 0.00
  • SCYX 0.05
  • MACD
  • HIT 0.00
  • SCYX -0.01
  • Stochastic Oscillator
  • HIT 0.00
  • SCYX 9.61

About HIT Health In Tech Inc. Class A Common Stock

Health In Tech Inc is an insurance technology platform company. It offers a marketplace that processes in the healthcare industry through vertical integration, process simplification, and automation. The group removed friction and complexities, it streamlined the underwriting, sales, and service process for insurance companies, licensed brokers, and TPAs.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: